Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

2 weeks ago

Achieved $20.1 million in OJEMDATM ( tovorafenib ) net product revenue ...

Ticker	Sentiment	Impact
DAWN	Neutral	8 %